You just read:

CMX157 Advances Head-to-Head Phase 2a Clinical Study in Hepatitis B Patients with Favorable Recommendation from DSMB

News provided by

ContraVir Pharmaceuticals, Inc.

17 Oct, 2016, 06:00 ET